The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluating longitudinal toxicity of cetuximab in patients with metastatic colorectal cancer (mCRC): A pooled analysis from 1,302 patients in the ARCAD database.
 
Guilherme Lopes
Stock and Other Ownership Interests - Pfizer
Research Funding - Merck Serono (Inst)
 
Jane Yeojeong So
Travel, Accommodations, Expenses - Roche
 
Katrin Marie Sjoquist
Honoraria - AMGEN; BMS; Ipsen; Merck; SERVIER
Consulting or Advisory Role - Competitive Drug Development International
Research Funding - Bayer (Inst)
 
Curtis L. Olswold
No Relationships to Disclose
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Carsten Bokemeyer
Honoraria - AstraZeneca; Bayer; Berlin-Chemie; Berlin-Chemie; Bristol-Myers Squibb; Merck KGaA; Merck Sharp Dohme; Roche; Sanofi
Consulting or Advisory Role - AOK Health Insurance; Bayer Schering Pharma; GSO; Lilly/ImClone; Merck Serono; Merck Sharp & Dohme; Novartis; Sanofi
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Agile Therapeutics (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); Apellis Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Glycotope GmbH (Inst); Incyte (Inst); IO Biotech (Inst); Isofol Medical (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Millennium (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Springworks Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Pfizer; Sanofi
 
Richard Adams
Honoraria - Amgen; Merck Serono; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; SERVIER
Speakers' Bureau - Merck Serono
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck Serono; SERVIER
 
Benoist Chibaudel
Honoraria - Bayer; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - BeiGene; Roche; Sanofi; SERVIER
Travel, Accommodations, Expenses - Merck; MSD; Roche; Sanofi
 
Axel Grothey
Honoraria - Aptitude Health; Elsevier; IMEDEX
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech/Roche; Lilly (Inst); OBI Pharma
Research Funding - Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bayer; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck; Takeda
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Aimery De Gramont
No Relationships to Disclose
 
Qian Shi
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Merck
Consulting or Advisory Role - Boehringer Ingelheim; Yiviva
Research Funding - Celgene (Inst); Roche/Genentech (Inst)
 
Christophe Tournigand
Honoraria - Bayer; Bristol-Myers Squibb; MSD; Roche; Sanofi
Consulting or Advisory Role - Bayer
Research Funding - Roche
Travel, Accommodations, Expenses - Bayer; MSD; Roche
 
John Raymond Zalcberg
Stock and Other Ownership Interests - Acceleron Pharma; Aimmune; Alnylam; Amarin Corporation; Biomarin; Concert Pharmaceuticals; Frequency Therapeutics; Gilead Sciences; Global Blood Therapeutics; GW Pharmaceuticals; Madrigal Pharmaceuticals; Moderna Therapeutics; Myovant Sciences; Opthea; Orphazyme; Sangamo Bioscience; Twist Bioscience; UniQure; Vertex; Zogenix
Honoraria - Deciphera; Gilead Sciences; Halozyme; Merck Serono; Specialised Therapeutics; Targovax
Consulting or Advisory Role - Center for Emerging & Neglected Diseases (CEND); Deciphera; Halozyme; Lipotek; Merck Serono; Merck Sharp & Dohme; Specialised Therapeutics; Targovax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); Merck Serono (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Merck Serono; Merck Sharp & Dohme; Sanofi